Photocure logo — The Bladder Cancer Company

Photocure

The Bladder Cancer Company

Founded 1993 Norway Norway 121 employees Biotechnology, Health Care +1

General Information

Company Name Photocure
Founded Year 1993
Location Norway Norway
Employees 121
Industries Biotechnology, Health Care, Pharmaceutical
Social

BounceWatch is an independent company data service, not affiliated with Photocure. To contact Photocure, visit photocure.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Photocure compare?

A PDF of Photocure and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Photocure soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Photocure

Photocure, known as "The Bladder Cancer Company," is a biotechnology firm based in Oslo, Norway and was founded in 1997. The company focuses on delivering transformative solutions to improve the lives of bladder cancer patients. Their unique technology, which makes cancer cells glow bright pink, has significantly improved health outcomes for patients globally. Photocure is publicly traded on the Oslo Stock Exchange (OSE: PHO) and is actively engaged in uro-oncology and company activities. Although the content shared by the company is for informational purposes only and not a substitute for medical advice, it has garnered attention from investors and the medical community. For more information, visit www.photocure.com, www.hexvix.com, www.cysview.com. With Photocure's innovative technology and strong presence in the biotechnology, healthcare, and pharmaceutical industries, it is a promising candidate for investment consideration. As of now, there is no publicly available information regarding the company's last investment or the involved investors.

Business keywords: Bladder Cancer, Uro-Oncology, Medical Technology, Cancer Treatment, Oslo Stock Exchange, Innovative Technology, Health Tech, Norwegian Companies, Publicly Traded, Cancer Diagnosis, Patient Outcomes, Hexvix, Cysview

No funding data available for Photocure yet.

Photocure Alternatives & Competitors

Photocure vs
ViewRay, Inc.
ViewRay, Inc. United States

Conquer cancer by re-envisioning radiation therapy.

Post-IPO Debt
76 employees
Biotechnology, Health Care
Photocure vs
RayzeBio
RayzeBio United States

Targeted innovative radiopharmaceuticals for cancer

Acquired
258 employees
Biotechnology, Health Care
Photocure vs
NovaScan
NovaScan United States

Easy to use ex vivo and in vivo cancer detection that provides instantaneous, highly accurate result...

Convertible Note
16 employees
Biotechnology, Health Care
Also compare with: Photocure vs Imagin Medical Imagin Medical

FAQ About Photocure

The Bladder Cancer Company
Photocure was founded in 1993.
Photocure is headquartered in Norway.
Photocure operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Bladder Cancer, Uro-Oncology, Medical Technology and Cancer Treatment.
Photocure has approximately 121 employees.
Top alternatives and competitors to Photocure include ViewRay, Inc., RayzeBio, NovaScan, Caedo Oncology AS, Imagin Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Photocure and ViewRay, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Photocure, https://bouncewatch.com/company/photocure, updated 28 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes